Co-Diagnostics, Inc. (CODX)

Market Cap	10.22M
Revenue (ttm)	3.92M
Net Income (ttm)	-37.64M
Shares Out	31.93M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	824,765
Open	0.3798
Previous Close	0.3915
Day's Range	0.2803 - 0.3798
52-Week Range	0.2803 - 2.2300
Beta	1.30
Analysts	Hold
Price Target	1.00 (+212.5%)
Earnings Date	Mar 27, 2025

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addi...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 12, 2017
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: CODX
• Website: https://co-dx.com

Financial Performance

In 2024, Co-Diagnostics's revenue was $3.92 million, a decrease of -42.53% compared to the previous year's $6.81 million. Losses were -$37.64 million, 6.53% more than in 2023.

Analyst Forecast

According to one analyst, the rating for CODX stock is "Hold" and the 12-month stock price forecast is $1.0.

Price Target

$1.0

(212.50% upside)

Analyst Consensus: Hold